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1. Introduction 
The first nasal spray pumps were developed some 50 years ago and replaced step by step 
droppers and pipettes. Now they are widely used to moisturize the nasal mucosa using 
saline solutions (from a regulatory point of view considered medical devices under the EU 
directive) or as nasal preparations for the administration of topically acting drugs (e.g. nasal 
decongestants or nasal steroids) or for the non-invasive administration of substances which 
need to reach systemic circulation (anti-migraine medication, hormones). For chronic 
diseases like allergic rhinitis, multi-dose devices are very cost effective and convenient and 
provide the safety and precision regulatory bodies require. To date, most of the medications 
administered nasally contain a preservative to support long storage times and proper in-use 
stability.  
For ophthalmic drugs, there was a similar development from simple droppers to more 
sophisticated devices. Squeeze bottles without metering function are still widely used for 
ophthalmic medications especially for chronic conditions. Artificial tears filled in multi-dose 
bottles are commonly used to relieve dry eye symptoms, these again being medical devices 
because the mode of action is purely physical. Looking at active drugs, the most successful 
in the ophthalmic field are drugs (e.g. beta-antagonists and prostaglandine-analogues) for 
the treatment of glaucoma and anti-histamines to treat allergic conjunctivitis.  
The reader may wonder why nasal spray pumps together with multi-dose ophthalmic 
droppers are considered in the very same chapter. The answer is that both device classes 
share the same blueprint: they use a bottle made of plastic or glass attached to a pump or 
dropper which generates and delivers a more or less metered dose and on top of this serves 
as a closure. So the pumps or droppers support two general functions: 
- Sealing of the container and protection of the content during storage and transportation. 
- Delivery of a metered dose of liquid or viscous pharmaceutical formulation. 
The major challenge during development is to reach a reliable delivery of the metered dose 
without having any negative impact caused by drug-device interactions. 
2. Intranasal administration 
Intranasal administration has a long tradition. Around three thousand years ago intranasal 
application of dried scabs was used to vaccinate against smallpox in India. Later intranasal 
administration of psychotropic drugs was and still is used for medical as well as recreational 
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purposes. Leaving these ancient therapeutic regimes behind, today the topical treatment of 
allergic rhinitis using anti-histamines (azelastine, levocabastine, olopatadine) or 
glucocorticoids (e.g. budesonide, fluticasone or ciclesonide) is well established. For this 
particular indication, drugs should act fast and just locally while systemic absorption should 
be as low as possible to avoid systemic side effects which are linked with typical oral 
formulations of comparable drug substances. Since allergic rhinitis is a chronic disease, only 
multi-dose bottles are used there.  
 
 Preferred profile 
Nasal decongestants 
e.g. oxymetazoline, xylometazoline, 
naphazoline, tetryzoline 
 
Local activity only, low systemic adsorption to 
minimize side effects (headache and dizziness) 
Intranasal steroids 
e.g. beclomethasone, budesonide, 
fluticasone, mometasone, ciclesonide 
 
Local activity only, low systemic adsorption to 
minimize systemic side effects (cortisol 
suppression) 
Antihistamines 
azelastine, levocabastine, olopatadine 
 
Local activity only, low systemic adsorption to 




Fast onset of action, high systemic adsorption to 
blunt migraine attacks 
Analgesics 
fentanyl, ketorolac, (ketamine)  
 
Fast onset of action but avoid high plasma 
concentration peaks  
Table 1. Established drug classes for intranasal administration 
But intranasal administration has much more potential. The nasal mucosa can be used for 
non-invasive systemic administration of drugs. The nasal mucosa in humans is around 
150 cm2, a surface which is well supplied by blood vessels. This ensures a rapid absorption 
of most drugs and can generate high blood levels. This administration route avoids the first 
pass metabolism which needs to be taken into account following oral administration. This 
bypassing of the gastric system even enables the delivery of peptide hormones. Calcitonin 
and desmopressin are on the market for years now, insulin and glucagon under clinical 
development for this administration route (Leary et al., 2008).  
Intranasal administration is considered a non-invasive administration route and easy to do 
for self-administration or for care-givers with low potential for injuries or disease 
transmission (hepatitis B, HIV). This is of special importance if fast pain relief is required 
and patient’s ability to deal with injections is impaired. Intranasal triptanes for migraine 
treatment, fentanyl to stop breakthrough pain and ondansetrone to relieve nausea take 
advantage of this administration route. For these indications, single dose devices or multi-
dose devices with counting or lock-out mechanisms are available to reduce the risk of 
unintended overdosing or misuse. 
A controversial discussion is ongoing regarding direct nose to brain drug delivery. This 
would open the door to a targeted treatment for various CNS diseases like Alzheimer, 
Parkinson, and epilepsies. Unfortunately, the available literature does not suggest consistent 
findings, more research is required here (Wen, 2011). 
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 Indication  Bioavailability [%] 
Azelastine Topical anti-histamine 40 
Budesonide Topical glucocorticoid 34 
Fentanyl Opiate analgesic 80-90 
Sumatriptan Anti-migraine 16 
Calcitonin Bone mineralization, polypeptide (32 amino acids) ~3 
Desmopressin Antidiuretic and anti-heamophilic, cyclic 
nonapeptide 
10-20 
Insulin Antidiabetic (peptide hormone, 51 amino acids) 12-15% 
Table 2. Nasal bioavailability of selected drugs (marketed or in late stage development) 
For the successful development of a nasal spray it is important to understand the basic 
mechanisms of such a device to recognize the cliffs which must be avoided. Of course a 
product intended to be administered as a nasal spray should have no unpleasant smell, 
should not be irritating and even long term treatment should have no negative effects on the 
nasal mucosa (e.g. ulceration, loss of sense of smell). There should be also no safety concern, 
if a dose is unintentionally shot into the eyes.  
For most pumps the dispensed volume per actuation is set between 50 and 140 µl, and an 
administered volume of 100 µl per nostril is optimum in adults. Higher volumes are prone to 
drip out immediately or to flow down into the throat (post nasal drip) and subsequent 
swallowing. So the anticipated dose should fit into a volume of roughly 100-200 µl when both 
nostrils are sprayed. Standard spray pumps will deposit most of the sprayed dose into the 
anterior region of the nasal cavity. Surface tension of the droplets and mucus layer will cause 
the immediate spread of the spray. Afterwards mucociliar clearance will distribute the liquid 
layer within the nasal cavity. Since the nasal mucus layer is continuously renewed and 
discarded into the throat, the nasal dwelling time of the administered drug depends on how 
fast it dissolves within the mucus layer and penetrates into the mucosa (Suman et al., 2002). 
Although authorities require a lot of data to describe nasal spray devices, for deposition 
efficiency the plume angle and administration angle are critical factors, while many other 
spray parameters, including particle size, have relatively minor influences on deposition 
within the nasal cavity (Foo et al., 2007). These parameters will be discussed in more detail 
below. 
3. Available technology and requirements 
3.1 First steps to identify the right spray pump 
Developing a suitable formulation with one or more active ingredients is a lengthy and 
challenging process. Rarely is a formulation just a simple water-based solution. Auxiliary 
compounds often have to be added, for example to enhance solubility and stability, to 
increase viscosity or to prevent microbiological contamination. Once the final formulation is 
available, the next step is to ensure that the ingredients do not affect the function and 
integrity of the container closure system (CCS). In the ICH guidelines it reads as follows: 
The suitability of the container closure system used for the storage, transportation 
(shipping) and use of the drug product should be discussed. This discussion should 
consider, e.g., choice of materials, protection from moisture and light, compatibility of the 
materials of construction with the dosage form (including sorption to container and 
leaching) safety of materials of construction, and performance (such as reproducibility of the 
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dose delivery from the device when presented as part of the drug product (ICH Guideline, 
2005). The two topics we want to focus on are compatibility and performance. 
To understand the potential problems an insight into the technology of a nasal spray pump 
system seems beneficial. 
The manufacturer fills the drug formulation into multi-dose bottles made of glass or 
different plastic materials, which are closed by attaching the spray pump including a dip 
tube. The pump may be fixed by a screw closure, crimped on or simply snapped onto the 
bottle. Now the system should be tight and no leakage should be observed during 
subsequent handling. During shipment and storage, the drug formulation is only in contact 
with the bottle, the outer side of the dip-tube, the gasket between the pump and the bottle 
and the outer parts of the pump. It is important to recognize, that in this stage the 
formulation usually does not have contact with inner parts of the pump nor the actuator. So 
the bottle will provide the largest surface but also the gasket material should be considered 
when stability issues (e.g. drug sorption, leachables) occur. 
Before someone can use the system, the pump must be primed which is normally done by 
the patient just before first use. A number of priming strokes are required to purge the air 
off the system and dip tube and to deliver the product at the targeted dose volume. Nasal 
spray pumps are displacement pumps. When actuating the pump, a piston moves 
downward in the metering chamber. A valve mechanism at the bottom of the metering 
chamber will prevent backflow into the dip tube. So the downward movement of the piston 
will create pressure within the metering chamber which forces the air (before priming) or 
the liquid outwards through the actuator and generates the spray.  When the actuation 
pressure is removed, a spring will force the piston to return to its initial position. This 
creates a vacuum in the metering chamber which pulls the liquid from the container by 
lifting up the ball from the ball seat above the dip tube at the bottom of the metering 
chamber. It should be recognized, that the “next dose” may be under normal use conditions 
in contact with the materials for hours or even days when the pump is not regularly used.  
 
 
Picture 1. Parts for a standard pump and how it looks like when assembled. On the right 
side: soaking of parts in formulation to check compatibility. For demonstration just parts for 
one pump are depicted. 
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It is recommended to evaluate effects on proper device function and compatibility of all 
parts which come in contact with the formulation early in the development process. This can 
be done in a simple way: disassembled pumps are stored for some days in the drug 
formulation under controlled conditions. This is done because some ingredients may cause 
swelling of plastic materials which may result in malfunction of the system. After 
appropriate storage time the parts are checked for discoloration and critical dimensions. 
Then the components of the pump system are cleaned and assembled and the proper 
function of the pump is evaluated. If the pump performs according to the agreed 
specification further problems are unlikely and the evaluation of performance parameters 
can start. These simple procedures can detect incompatibilities quite early and it is much 
better than to find out such issues later in the development stage or even after market 
launch due to complaints from consumers and patients. 
3.2 General requirements from authorities  
According to EU and FDA guidelines (EMEA guideline, 2006, FDA Guidance for Industry 
2002) relevant information should be provided on the characteristics of each of the critical 
components of the CCS. Critical components are defined as: 
- those that come into contact with the patient’s mouth or nose or with the formulation 
- those that affect the overall performance of the device and 
- any additional protective packaging (FDA Guidance for Industry)  
Within this chapter we cannot discuss all requirements in detail, but will provide an 
overview on the most important parameters (also see Table 3). For most parameters you just 
need to know that they are required and the pump supplier will disclose this information by 
providing the appropriate files or via referencing a drug master file type III for the US FDA. 
 
Dimensions and used materials 
Dimensions Critical dimensions for all individual components and 
drawings of the device and detailed description of all 
parts, manufacturing and assembly steps
Material used Documentation on raw material, additives (e.g. colors, 
stabilizers) processing aids (e.g. lubricants) used for 
manufacturing including source and quality control 
Performance 
Shot weight/dose weight the quantity of drug substance/spray weight expected to 
be released from the device during actuation 
EU: mean shot weight/dose within ±15% of target dose 
US: mean shot weight/dose within ±10% of target dose 
For small doses (<20 µg) other criteria may be justified 
Priming Number of actuations needed to prime/re-prime the 
pump and obtain the full dose
Droplet size distribution Description of droplet size distribution and 




Parameters to describe size, shape and pattern of a 
delivered spray
Actuation force Minimum actuation force to achieve desired spray 
characteristics 
Table 3. Key requirements for nasal spray pumps 
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3.3 Overall general description of the device and compatibility issues 
The pump manufacturer needs to provide technical drawings of the assembled device as 
well as for each individual part with critical dimensions which are controlled during 
production. Also the manufacturing of each part and the assembling process needs to be 
described in detail, additional operations like washing or coating steps, sterilization 
procedures and of course detailed quality control measures. 
Since nasal sprays and drops are liquid medications, there is a high likelihood of 
interactions between the immediate packaging and the formulation. Therefore high quality 
standards for the used materials must be met. Preferably, only material is used which is 
described in a Pharmacopea or in foodstuff legislation (EMEA Guideline, 2005). Of course 
other materials may be also used but in such a case an extractable profile and complete 
documentation on safety and toxicology needs to be generated and submitted.  
So all used materials must be identified including the monomers, any additives or colors 
used and the suppliers for the raw material must be disclosed. To deal with it, it is 
important, that the manufacturer of the devices has an established quality and change 
control process which documents all changes and gives notice to customers when required.  
 
 
Even when material of high quality is used for the devices some interactions with the 
formulation can occur.  
To ensure proper function of the pump, steel springs and balls are used which may be in 
contact with the formulation. Any metal components like balls and springs are prone to 
cause problems. Even if they are made of non-corrosive material, the surface can discolor 
the formulation due to impurities or contamination with lower grade material during the 
manufacturing process. Another risk coming from metal parts are remaining lubricants, 
which can contaminate the product.  
Polyoxymethylene (POM), a widely used material for gaskets and pump parts can release 
formaldehyde into the drug. Materials like polyethylene or polypropylene are less likely to 
cause problems, but some monomers or additives can leach into the formulation.  This 
problem of leachables coming from the pump is sometimes overlooked, because during the 
standard stability studies with non-primed pumps no interaction will be seen with parts inside 
the pumps. When the pumps are tested for dose consistency, the bottle will be emptied within 
a few hours. So it is recommended to evaluate compatibility of all parts which come in contact 
with the formulation as described above early in the development process.  
3.4 Performance parameters 
As already mentioned, plume geometry and administration angle have the most significant 
influence onto nasal deposition but some more parameters are required by authorities for 
nasal sprays and will be discussed briefly. 
It should be clear that the parameters discussed below depend on the experimental 
conditions and the equipment used for the characterization. So it is important to use well 
Definitions 
Extractables: compounds which may be extracted from the container closure 
system by using stressful conditions.  
Leachables: compounds which may leach from the container closure system into 
the formulation under normal conditions of storage and use. 
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controlled conditions (e.g. automated actuation at defined speed or force) and procedures 
for the measurement of performance parameters. From experience it can be told, that the 
combination of a particular spray pump with a formulation will result in a quite unique 
performance profile which is hard to meet when considering the use of another pump. The 
US-FDA recognized that and recommends for generic nasal sprays to use the same brand 
and model of devices (particularly the metering valve or pump and the actuator) as used in 
the reference product to get equivalence on the basis of in vitro tests (FDA Guidance for 
Industry, 2003). 
3.4.1 Spray pattern and plume geometry 
The spray pattern is best described as a horizontal cut through the spray plume at a defined 
distance from the orifice, in most cases set at 30 mm. It can be assessed by simply spraying a 
stained formulation on a sheet of paper or thin layer chromatography (TLC) plates. For TLC 
plates some chemical reactions may be used to develop the pattern, which is considered 
more accurately. A higher sophisticated method is the use of a laser beam for the 
measurements, with systems e.g. from Proveris Scientific, Malvern Instruments, Oxford 
Lasers or InnovaSystems to name the most widely known providers.   Then the shape (e.g. 
round or ellipsoid shape) and dimensions (e.g. shortest and longest axis) are evaluated and 
the spray angle may be calculated from this data.  
 
 
Picture 2. Spray pattern (left) and plume geometry (right) measurements and derived 
parameters using a laser-based system (Equipment: Proveris Scientific SprayVIEW® and 
analysed by Proveris Scientific Viota software). 
The plume geometry describes the shape and size of the plume (length, width, spray cone 
angle) at a defined time point following actuation, preferably during the fully developed 
phase. These parameters are closely linked to a good nasal deposition but are also important 
for evaluating the performance of the pump. It is recommended to test a range of pumps for 
a new formulation, because various factors affect the spray pattern and plume geometry, 
e.g. the size and shape of the nozzle, the design of the pump, and the size of the metering 
chamber. On the other side, these parameters are quite sensitive to changes in dimensions 
within the spray pump as well as changes in the formulation. For these reasons, the spray 
pattern is often used for quality control purposes.  
3.4.2 Particle-size distribution 
The nose is a very effective filter and most particles and droplets will be caught within the 
nasal cavity. Only particles less than 10 µm median aerodynamic diameter, so called fine 
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particles, can reach the lower airways during nasal breathing (Stuart 1984). Most spray 
pumps will generate an aerosol with a mean particle size in the range of 20-100 µm which 
are recognized as fine mist and will deposit well in the nasal cavity. During the formation 
and dissipation phases much larger droplets (>300 µm) can be formed. Droplet size 
distribution for nasal sprays is assessed by laser diffraction methods. Results are typically 
expressed as a size in microns below which 10%, 50% or 90% of the volume (DV or mass DM) 
of material exist (e.g. DV10, DV50, DV90, span) and percentage of droplets less than 10 µm. 
Although a wide range of particles will certainly deposit in the nose, authorities require 
their characterization because it is a sensitive parameter to detect changes in pump quality 
or in the formulation.   
3.4.3 Actuation force 
Nasal spray pumps are normally actuated by a fast movement of thumb, index and middle 
finger. More recently also pumps with side actuation became available. When actuated, the 
pumps should deliver the whole dose as fine mist within a fraction of a second. Actuation 
forces should be in the range of 30-80 N (~3-8 kg). As a rule of thumb, higher viscosity will 
require higher actuation force. Of course there is also a great impact coming from the device 
side. Geometry of the metering chamber, design of the valve mechanisms, internal friction, 
spring forces, dimensions of the swirling chamber have a great influence on this parameter. 
Some of them can be adapted by the manufacturer to a certain degree to meet the 
requirements of a particular formulation. Beside this, it is always recommended to test 
several pump types with a new formulation to find the best match and to meet requirements 
of the target group (children, elderly). 
 
 
Picture 3. Standard nasal spray pump on the left: This pump is actuated by pressing the 
actuator in a longitudinal movement towards the bottle. On the right side a nasal spray 
pump (Latitude®) designed for lateral actuation with the thumb which is preferred by some 
people. 
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3.4.4 Shot weight and delivered dose 
Methods for the measurement of shot weight or delivered dose and acceptance criteria are 
well described in the appropriate guidelines. It should be recognized, that there are some 
differences between European and US guidelines which should be considered during 
development.  
The volume of the metering chamber will define the delivered dose for a primed pump. This 
works normally fine for water or saline when the right actuation parameters (force, stroke 
acceleration) are used. Depending on surface tension and viscosity of the product, air may 
be trapped in the dosing chamber influencing priming and dose accuracy. Similar problems 
may occur when air bubbles come into the dip tube. Also too low actuation forces may lead 
to partial metering. To overcome the problem of partial metering, so called “user-
independent” spray pumps were developed but are not widely used by the industry yet.  
4. Bottles 
Bottles or containers are an integral part of drug delivery devices and will also influence the 
general appearance of the final product. Special shapes may be used to differentiate a 
product from competitors. Glass bottles are less prone to cause interactions and will give 
good protection to the formulation even during long storage intervals. Sometimes the glass 
can influence the stability of the formulation (change in pH, release of trace metals). This 
depends of course on the quality of the glass which is described by its hydrolytic class 
(hydrolytic class I-III is normally used for pharmaceutical products). The disadvantages 
which glass bottles may have are the higher weight and the risk to break when dropped. 
Bottles made of plastic material (e.g. polyethylene, polypropylene, PET) are sometimes used 
for nasal sprays but are mandatory for ophthalmic droppers because squeezing the bottles is 
needed to dispense the product. Pump supplier will most likely not manufacture these 
bottles themselves because a complete different technology is used. Parts for spray pumps 
or droppers are quite exclusively made by injection molding which gives high precision. 
Plastic bottle manufacturers use a process called blow-molding. The general principle is to 
make a hollow raw part and then blowing up the material to the final dimensions. The most 
important disadvantage for all bottles made of plastic material is evaporation/weight loss. 
Plastic materials are not a perfect barrier for gas or water evaporation. This problem can be 
tackled using laminated materials but these are more expensive. Another potential risk has 
to be considered: inks and adhesives from labels may migrate through the bottle wall and 
leach into the formulation. 
Pure mechanics but critical for all types of bottles: the bottle opening must fit the delivery 
device exactly. It needs to be tested and dimensions need to be controlled because variations 
may cause leakages or destroy the closure during final assembly. To avoid troubles, 
consultation of the delivery system supplier is highly recommended as these companies are 
experienced in managing this interface. The pump supplier should be able to recommend a 
range of suited bottles from suppliers which provide reliable quality. Before switching to 
another bottle or bottle supplier, the compatibility with the device should be checked in 
advance.  
5. Use of preservatives in multi-dose products 
Multi-dose dispensers are widely used for the administration of liquid nasal, ophthalmic or 
dermal drugs because they are convenient and cost effective. To prevent degradation of the 
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product and to avoid the spread of potentially harmful microbes the content has to be kept 
sterile, both during storage and while in use by the patient or consumer. This requirement is 
in most cases met by a closely controlled manufacturing and filling procedure and by 
placing a suitable preservative or a combination of multiple preservatives in the 
formulations. Benzalkonium chloride (BAC) is by far the most widely used preservative, but 
thiomersal, chlorhexidine, chlorobutanol and phenylethanol, and parabens can also be 
found in topical medications (Freeman and Kahook, 2009).  
Two general issues are linked to the use of these preservatives, one of which is the choice of 
materials. This is certainly of primary importance for the manufacturer only. Traditional 
glass containers do not interact with preservatives, but more and more used plastic 
containers and dispensing devices pose problems such as permeation of preservatives 
through the container or interaction with the plastic materials used in these. Rubber also 
reacts with preservatives but it is still used for closures, which in such events have to be pre-
treated with the preservatives to minimize subsequent uptake during storage. 
The issue of significance for the patient and consumer, however, is the high incidence of 
local side effects attributed to preservatives. The discussion is controversial, and published 
preclinical and clinical studies are not always consistent. It seems to be clear that short-term 
use of preparations containing preservatives at low concentrations is well tolerated, but 
preservatives can cause serious inflammatory effects with long-term use. The responses may 
include chemical irritation, hyperreactivity and true allergies (Hong and Bilory, 2009). The 
German Authorities (BfArM) addressed the use of BAC for nasal sprays in 2003 (BfArM 
notice, 2003) which pushed the preservative free systems for this administration route. Only 
recently, European authorities encourage the use of unpreserved multi-dose dispensers 
even for ophthalmic use (EMEA public statement, 2009).  
Systems allowing multi-dose use of unpreserved formulations have the potential to solve 
some of the problems faced by pharmaceutical manufacturers (e.g. incompatibilities), as 
well as offer marked benefits for patients in need of chronic treatment. The technology starts 
to get widely known as PFMD devices (preservative free multi dose). 
When using a preserved or unpreserved multi-dose product, there are three ways for 
microorganisms to enter the system: 
- via the orifice and 
- via the venting air which is replacing the dispensed liquid or 
- insufficient container/dispenser fit. 
In preserved formulations (conventional system), the added preservative controls microbial 
growth and no additional measures need to be taken to prevent microbial occupation via the 
orifice or venting air. If the formulation does not contain preservatives, the device must be 
able to keep microorganisms out off the system.  
Today a range of technical solutions is available to overcome this issue. The highest risk of 
contamination obviously comes from the orifice, because it may come in contact with skin 
and mucosa as well as with infected body fluids. Some marketed systems use the 
oligodynamic activity of a silver wire in the tip of the actuator, a silver coated spring and 
ball (Groß, 2000). These components release silver ions into the formulation, which is a time 
dependent process. The system is able to keep microorganisms down between long dosing 
intervals, even when the tip is immersed into bacterial contaminated fluid (Bagel and 
Wiedemann, 2004). Silver ions are widely used for their antiseptic properties and even when 
used for wound dressings, it is safe and no adverse effects are attributed to this treatment. 
One general limitation of course must be considered: the silver ions may react with the 
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formulation, e.g. chloride ions and form micro-precipitations. This effect may be overlooked 
because it is most relevant for spans of 6-12 hours between individual actuations which are 
not routinely tested during development.  
 
 
Picture 4. Examples for ophthalmic devices using the oligodynamic effects of silver in 
combination with other measures like collapsing bags or sterile filtration of the venting air. 
Consequently, the most recent preservative free systems follow a purely mechanical 
approach to minimize interactions between parts of the device and the formulation. One 
technical solution to prevent contamination via the orifice is named “tip seal technology” 
which may be utilized for both nasal spray pumps and ophthalmic droppers. A spring 
loaded valve is located directly below the opening of the tip orifice and does not allow any 
microbes to migrate from any surfaces or contacted liquids into the system, the orifice is 
“sealed” under resting conditions. The tip seal keeps the system closed until a defined 
pressure (for nasal sprays it is more than 3 bar) is reached by actuating the system. Then the 
system will open and the formulation is forced through the orifice with a higher pressure 
than needed to open the valve. When the pressure drops at the end of the actuation the tip 
seal will immediately close the orifice with an outward movement. So no backflow of 
potentially contaminated medication or other liquid is possible. Depending on the pump 
system, the fluid path may even be “metal-free”, which means the springs needed for the 
device operation do not come in contact with the formulation.  
To avoid contamination of the formulation via venting air different technical solutions are 
used. The simplest way is sterile filtration of the venting air using separate filters or filter 
gaskets. For oxygen-sensitive formulations, so called collapsing bags or depressed systems 
are used. The formulation is filled in a special, microbial tight bag which is protected by a 
surrounding bottle. When dispensing the product, the bag collapses with the content not 
coming in contact with the ambient air. Some pumps are constructed in such a way, that the 
whole system is air-thigh and during use a certain vacuum (up to -300 mbar) is generated 
within the bottle. Those systems allow even a purging with inert gases to reduce oxygen 
content in the container head space. 
These approaches to avoid the use of preservatives for multi-dose devices sound 
complicated but are well established and mature technologies. Preservative-free single dose 
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containers, most often presented as blow-fill-seal (BFS) containers can be an alternative for 
short term treatments. Disadvantages of these systems are linked to the quite complicated 
filling technology, the need to overfill and amount of material needed for each dose. Any 
efforts to provide reliable preservative free multi-dose systems are certainly appreciated by 
the growing number of patients who experienced discomfort with preserved formulations. 
 
Prevent contamination via orifice  
Oligodynamic components in the 
actuator or inside the pump 
Open orifice, but silver-ions are released into the 
formulation which kills germs but may interact 
with the formulation 
“tip-seal” technology Mechanical barrier system to prevent bacterial 
contamination 
Prevent contamination via venting air
Sterile filter incorporated into delivery 
system 
The venting air in pressure balanced systems are 
forced though sterile filters with pore sizes less 
than 0.2 µm, the filter membranes are normally 
hydrophobic which prevents leakage from liquids 
out of the container via the venting system 
Collapsing primary container Best suited for oxygen-sensitive formulations, 
because the venting air does not come in contact 
with it, this technology also enables spraying at 
different angles
Unvented container/pump system Tight fit of bottle and pump design prevent 
venting of the bottle, vacuum up to -300 mbar are 
reached
Table 4. Measures/technical solutions for preservative free multi-dose devices 
5.1 Preservative free ophthalmic devices 
With aging populations, conditions which require chronic treatment like dry eye syndrome 
or glaucoma are on the rise (WHO fact sheet, 2009) and preservative free multi-dose devices 
come into play. Chronic use of preserved formulation is not always tolerated by some 
patients. That is why the EMA encourages the development of such devices (EMEA public 
statement, 2009). This is not an easy task and poses some risks for the manufacturer. The 
standards for ophthalmic medications are set high to make sure that no patient or consumer 
‘risks an eye’. Agencies enforce guidelines on sterility of the product, absence of particles 
and microbial stability. Typically, the observation of microbial growth in a product leads to 
rejection of the entire batch, which will impact the manufacturer significantly. 
Production and filling of ophthalmic medications are highly sophisticated, so 
pharmaceutical manufacturers are reluctant to alter established processes or to invest 
substantially in new filling technologies that obviously require further process 
qualification.  
Because of these difficulties, only a very few multi-dose devices are available on the market 
yet, most of them relying on the oligodynamic effects of silver ions.  
A patient-friendly, multi-dose system for unpreserved liquids is what patients and 
consumers are looking for, regardless whether one considers “simple” products like 
artificial tears or more complex pharmaceutical products such as prostaglandins or the like 
for treatment of serious diseases such as glaucoma. 
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Picture 5. On the left: Rendered picture of the Ophthalmic Squeeze Dispenser (OSD) 
showing the tip seal and filter for the venting air in blue. Right: the complete system after 
filling and with removed protection cap. 
A break through approach may be the Ophthalmic Squeeze Dispenser (OSD) which uses the 
mechanical tip-seal technology combined with sterile filtration of the venting air known 
from preservative free nasal spray pumps. The OSD is simply actuated by squeezing a 
LDPE (low density polyethylene) bottle and will deliver a drop in the range of 35 µl. The 
device can easily be adapted for a certain range of viscosity to keep forces within a rational 
limit and to deliver a consistent drop. Not only is the dropper highly sophisticated but the 
bottle too. The thickness of the bottle wall must be a compromise between minimizing water 
vapor loss and providing acceptable actuation forces. Of course the fit between bottle and 
dropper must be perfect to avoid contamination via this way. As some ophthalmic 
formulations have compatibility issues with metal, the OSD features a metal-free fluid path. 
6. Microbial device integrity tests 
To introduce a preservative-free multi-dose device successfully on the market, the microbial 
integrity must be clearly demonstrated to customers and authorities. Although there are 
guidelines in place for preserved multi-dose and preservative-free single dose containers, 
there is no guideline on microbial testing of preservative-free multi-dose devices. So the 
industry has to develop convincing test methods on their own. A well known procedure is 
the so called Wiedemann test, which was developed to characterize the 3K/Comod-system 
(Bagel and Wiedemann, 2004). This test for nasal sprays focuses on the microbial load of the 
next sprayed dose and was developed according to the needs of the system which releases 
silver ions into the formulation. The acceptance criteria are less than 100 CfU/ml delivered 
dose (according the EU Pharmacopeia) and no contamination of the bottle content. Similar 
tests were developed using a very agile germ (Pseudomonas aeruginosa) for the tip seal test 
and the tiny and robust spores from Baccilus subtilis for the whole package integrity test. 
These tests may be used for the characterization of preservative-free multi-dose nasal spray 
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devices (Bommer et al., 2004) as well as for ophthalmic devices (Marx et al., 2010). For such 
device qualification tests most often the devices are filled with broth medium provide 
optimum conditions for the germs to growth in the case of any contamination. The final 
product will promote bacterial growth much less which provides more confidence. 
 
 
Picture 6. Microbial test to challenge the tip seal function and contamination of delivered 
doses with a preservative-free ophthalmic dropper. 
7. Summary 
The intranasal route can be used for a wide range of applications and administration 
procedure is safe and easy. On the other side, development of a nasal formulation and to 
identify the right device is a complex process. Cooperation with an experienced pump 
manufacturer and specialized test laboratories on the selection of the delivery system and 
setting the right specifications can save resources and increase probability of success. Selecting 
the wrong spray pump or bottle can jeopardize the entire project so a range of pumps should 
be tested early in the development process. In this chapter we have focused on multi-dose 
devices for liquids because they clearly dominate the market. In the future we will see more of 
so called unit-dose devices which deliver only one dose for one or both nostrils and are 
discarded then. Such devices can be used for the administration of controlled substances (like 
fentanyl) to reduce the risk of misuse or for vaccinations (Marx et al., 2011). There are also 
some propellant-driven devices on the market (e.g. for nasal steroids) but discussion about the 
impact on the environment may limit their success. The future will also see powders for 
intranasal administration but all known projects are still in various stages of clinical trials. Last 
not least electronic add-ons, such as counters or locking features, may bring advantages and 
opportunities in nasal drug delivery, but will obviously need to comply with cost challenges.  
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Picture 7. Microbial test to challenge the venting system and closure tightness for 
preservative free multi-dose systems. During the aerosol-exposure the systems are actuated 
to generate an under pressure within the system.  
Non-invasive administration of eye care products is still by far the most used way to reach 
therapeutic targets, let it be in diseases such as glaucoma or in self-medicated conditions 
such as dry-eye syndrome. Alternative methods such as implants or intravitreal injections 
are getting more attention lately, but given the implications associated with these methods it 
is fair to conclude that the multidose eye dropper still has a promising future. Avoiding or 
at least reducing the use of preserving agents in ophthalmic formulations is one way to 
maintain or extend life cycles of existing products and to ease acceptance of new entities. 
However, in particular in eye care habits of patients and consumers need to be taken into 
account carefully. 
To answer the question from the beginning: will drug formulations for multiple use, 
presented in multi-dose containers for nasal or ophthalmic drugs, become preservative free? 
The answer is not as easy to give as it seems, because cultural aspects are no less important 
than regulatory aspects, safety concerns or clinical findings. However, as seen today in 
Europe, a trend begins to establish itself towards preservative-free multi-dose formulations 
and, consequently, delivery systems, in order to meet patient’s expectations. Any 
development of novel drugs or research on life cycle management should take this into 
serious consideration. 
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